New preclinical findings presented by BeyondSpring Inc. at the AACR 2026 conference reveal that Plinabulin significantly enhances the efficacy of antibody-drug conjugates (ADCs) in cancer treatment. The combination of Plinabulin with leading ADCs, such as T-DXd (trastuzumab deruxtecan) and Dato-DXd (datopotamab deruxtecan), resulted in improved complete response rates and survival in preclinical models, demonstrating its potential to address critical limitations of current ADC therapies.

The data indicate that Plinabulin not only boosts anticancer activity but also improves tolerability, allowing for sustained treatment. Specifically, the combination therapies showed higher rates of complete tumor regression and significantly extended survival times. Additionally, Plinabulin reduced chemotherapy-induced neutropenia, a common side effect that often leads to dose reductions or treatment interruptions. This dual mechanism of enhancing immune responses—by increasing the CD8+ T cell/Treg ratio—and mitigating toxicity positions Plinabulin as a promising adjunct to existing ADC regimens.

The implications of these findings are substantial for the future of cancer treatment. Plinabulin’s unique GEF-H1 agonist mechanism not only complements ADCs but may also establish it as a backbone therapy across various ADC combinations. This positions Plinabulin to potentially transform treatment paradigms, particularly in settings where ADCs have not outperformed traditional chemotherapy. As BeyondSpring moves forward with the planned DUBLIN-4 confirmatory Phase 3 trial, these results underscore the need for innovative strategies to enhance ADC efficacy and patient outcomes in oncology.

Source: globenewswire.com